Literature DB >> 8819254

Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men--role of the metabolic syndrome.

M Cigolini1, G Targher, G Agostino, M Tonoli, M Muggeo, G De Sandre.   

Abstract

The relationship between liver steatosis, evaluated by ultrasonography, and various plasma haemostatic factors was examined in 64 apparently healthy males, aged 38 years. Plasma levels of factor VII clotting activity (F-VIIc), plasminogen activator inhibitor-1 (PAI-1) activity and antigen, tissue-type plasminogen activator (t-PA) activity significantly differed in men with liver steatosis (n = 31) as compared with those without steatosis (n = 33). No significant differences were found in t-PA antigen and F-VII antigen. The men with liver steatosis also had significantly higher body mass index (BMI), plasma triglyceride and 2 h post-load insulin concentrations. While the differences in plasma haemostatic factors were substantially unchanged after adjustment for BMI, they totally disappeared when further allowance was made for plasma triglyceride and 2 h insulin concentrations. In conclusion, these results indicate that liver steatosis correlates specifically with increased PAI-1, F-VIIc and decreased t-PA levels, and suggest that such a relation is largely mediated by concomitant alterations in plasma triglyceride and insulin concentrations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8819254

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  16 in total

Review 1.  Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?

Authors:  Margaret Spinosa; Jonathan G Stine
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

2.  Moderate vitamin A supplementation in obese mice regulates tissue factor and cytokine production in a sex-specific manner.

Authors:  Liubov V Gushchina; Rumana Yasmeen; Ouliana Ziouzenkova
Journal:  Arch Biochem Biophys       Date:  2013-07-11       Impact factor: 4.013

3.  Hepatic CD36 downregulation parallels steatosis improvement in morbidly obese undergoing bariatric surgery.

Authors:  E Pardina; R Ferrer; J Rossell; D Ricart-Jané; K A Méndez-Lara; J A Baena-Fustegueras; A Lecube; J Julve; J Peinado-Onsurbe
Journal:  Int J Obes (Lond)       Date:  2017-05-10       Impact factor: 5.095

4.  Protease-activated receptor 1 and hematopoietic cell tissue factor are required for hepatic steatosis in mice fed a Western diet.

Authors:  Karen M Kassel; A Phillip Owens; Cheryl E Rockwell; Bradley P Sullivan; Ruipeng Wang; Ossama Tawfik; Guodong Li; Grace L Guo; Nigel Mackman; James P Luyendyk
Journal:  Am J Pathol       Date:  2011-09-09       Impact factor: 4.307

5.  Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice.

Authors:  James P Luyendyk; Bradley P Sullivan; Grace L Guo; Ruipeng Wang
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

6.  Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease.

Authors:  Karen M Kassel; Bradley P Sullivan; Wei Cui; Bryan L Copple; James P Luyendyk
Journal:  Am J Pathol       Date:  2012-07-26       Impact factor: 4.307

7.  Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy.

Authors:  Antonio Barbato; Roberto Iacone; Giovanni Tarantino; Ornella Russo; Paolo Sorrentino; Sonia Avallone; Ferruccio Galletti; Eduardo Farinaro; Elisabetta Della Valle; Pasquale Strazzullo
Journal:  Intern Emerg Med       Date:  2009-04-07       Impact factor: 3.397

8.  Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.

Authors:  S Yener; M Akarsu; T Demir; B Akinci; O Sagol; F Bayraktar; M A Ozcan; E Tankurt; S Yesil
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

Review 9.  Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates .

Authors:  Naga Swetha Samji; Rajiv Heda; Sanjaya K Satapathy
Journal:  Transl Gastroenterol Hepatol       Date:  2020-01-05

10.  Evaluation of metabolic syndrome frequency and carotid artery intima-media thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease.

Authors:  Cem Aygun; Orhan Kocaman; Tayfun Sahin; Suleyman Uraz; Ahmet T Eminler; Altay Celebi; Omer Senturk; Sadettin Hulagu
Journal:  Dig Dis Sci       Date:  2007-10-16       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.